Apr 18 |
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
|
Apr 8 |
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
|
Apr 5 |
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
|
Apr 5 |
Ovid Therapeutics gains on bullish view at Wedbush
|
Mar 27 |
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
|
Mar 26 |
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
|
Mar 26 |
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
|
Mar 25 |
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
|
Mar 20 |
Puma Biotech cleared to trial Takeda-partnered breast cancer therapy in U.S.
|
Mar 19 |
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
|